Skip to content
drillr.ai
Sign up

TAK

Takeda Pharmaceutical Company Limited

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · JP

Also listed · 4502.T →
$19.61
−0.31%
Ask drillr

  • Oct 19, 2026, 09:30 UTC

    Takeda announced new VERDICT trial data showing that treating adults with ulcerative colitis with intravenous ENTYVIO to achieve corticosteroid-free disease clearance, rather than symptomatic remission alone, prolonged time to the first UC-related complication (hazard ratio 0.33; 95% confidence interval 0.17–0.67; P=0.0014).

    Source:

  • Oct 16, 2026, 14:00 UTC

    The UK High Court upheld Takeda’s supplementary protection certificate for lisdexamfetamine and rejected challenges by Aristo Pharma GmbH and STADA Arzneimittel AG.

    Source:

  • Oct 15, 2026, 22:15 UTC

    Takeda Pharmaceutical shares closed at 6,183 yen, up 294 yen.

    Source:

  • Oct 15, 2026, 00:30 UTC

    Takeda announced that ORZEYFUL (oveporexton) is now available in Japan and China for treating narcolepsy type 1.

    Source:

  • Sep 29, 2026, 11:25 UTC

    Aquestive Therapeutics, Inc. appointed Richard J. Daly as a director effective October 14, 2026, granting him 57,000 stock options under the company's 2018 Equity Incentive Plan.

  • Sep 28, 2026, 23:59 UTC

    The National Comprehensive Cancer Network included brigatinib (Alunbrig) in its Clinical Practice Guidelines in Oncology for Central Nervous System Cancers as a recommended treatment for NF2-related schwannomatosis.

    Source:

  • Sep 23, 2026, 17:45 UTC

    AbbVie, Astex Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly trained the federated AI model AISB-1-Fed on more than 20,000 proprietary protein–ligand structures in collaboration with Columbia University's AlQuraishi lab, achieving 52.1% high-quality interface predictions versus 35.6% for OpenFold3 Preview 2 and 40.9% for Boltz-2.

    Source:

  • Sep 23, 2026, 08:06 UTC

    Roche announced it will nominate Christophe Weber, former CEO of Takeda Pharmaceutical, for election to its board of directors at its March 2027 shareholders meeting.

    Source:

  • Sep 18, 2026, 11:30 UTC

    Takeda's QDENGA, a live-attenuated tetravalent dengue vaccine, is set to become India's first approved dengue vaccine, with private-market availability expected in the first half of 2027.

    Source:

  • Sep 18, 2026, 03:41 UTC

    Dr Reddy's Laboratories signed a distribution agreement with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.

    Source:

  • Sep 16, 2026, 09:33 UTC

    Takeda Pharmaceutical received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare for Elahere, an antibody-drug conjugate for FRα-positive platinum-resistant recurrent ovarian cancer, the first such ADC approved in Japan for this indication.

    Source:

  • Sep 16, 2026, 00:46 UTC

    On September 15, US-listed ADRs of Japanese companies traded with a slight selling bias, with Chugai Pharmaceutical and Takeda Pharmaceutical among the decliners, while Chicago Nikkei 225 futures settled at 63,405 yen, 285 yen above the Osaka daytime level.

    Source:

  • Sep 14, 2026, 07:00 UTC

    The U.S. FDA accepted Takeda's New Drug Application under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis.

    Source:

  • Sep 10, 2026, 21:45 UTC

    Former Takeda Pharmaceutical president and chairman Shigenori Hasegawa, who led the company's global expansion through large acquisitions, died.

    Source:

  • Sep 10, 2026, 09:34 UTC

    Takeda Pharmaceutical announced that Andy Plump, president of its research and development division, plans to retire effective June 2027.

    Source:

  • Sep 9, 2026, 13:00 UTC

    Rakuten Medical announced that Christophe Weber, former CEO of Takeda Pharmaceutical, has been appointed Vice Chairman of the Board, effective September 1, 2026.

    Source:

  • Sep 8, 2026, 20:05 UTC

    Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.

    Source:

  • Sep 2, 2026, 09:17 UTC

    Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.

    Source:

  • Aug 28, 2026, 21:39 UTC

    The U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.

    Source:

  • Aug 25, 2026, 11:58 UTC

    Takeda China announced a cooperation agreement with Ant Health on August 25, 2026, to explore digital technology applications in healthcare, including patient lifecycle management, physician digital empowerment, digital health ecosystem building, innovative payment models, and accelerating drug and new indication development.

    Source:

  • Aug 24, 2026, 06:36 UTC

    Takeda announced that Japan's Ministry of Health, Labour and Welfare approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults, making it the first and only medicine in Japan to address the underlying cause of the disease.

    Source:
Page 1Next →